PMID- 25891931
OWN - NLM
STAT- MEDLINE
DCOM- 20160104
LR  - 20220316
IS  - 1532-2688 (Electronic)
IS  - 1059-1311 (Linking)
VI  - 27
DP  - 2015 Apr
TI  - Lacosamide monotherapy for partial onset seizures.
PG  - 71-4
LID - S1059-1311(15)00073-4 [pii]
LID - 10.1016/j.seizure.2015.03.003 [doi]
AB  - PURPOSE: To evaluate the 1-year efficacy and safety of oral lacosamide as 
      conversion monotherapy in adult patients with partial onset seizures with or 
      without generalization. METHOD: We prospectively followed-up consecutive patients 
      converted to lacosamide monotherapy after 1-year seizure freedom on lacosamide 
      add-on therapy and withdrawal of the concurrent antiepileptic drug (AED). Seizure 
      occurrence, treatment compliance and drug toxicity were assessed every 3 months 
      up to 1 year. The study outcomes were the retention rate of lacosamide as single 
      AED and the seizure freedom under lacosamide monotherapy at 1 year from 
      withdrawal of background AED. The safety variable was the prevalence of 
      lacosamide related adverse events (AEs). RESULTS: Among the 58 included patients, 
      at 1 year from withdrawal of background medication, 37 (63.8%) retained 
      lacosamide as single AED and 32 (55.2%) were free from seizure occurrence under 
      lacosamide monotherapy throughout the entire follow-up. The history of less than 
      three lifetime AEDs turned out to be significant predictor of seizure freedom 
      (adjusted OR = 6.38, 95% CI 1.85-21.98, p = 0.003). Twelve (20.8%) subjects 
      reported mild to moderate AEs, with the commonest being drowsiness, dizziness, 
      and headache. CONCLUSION: Conversion to lacosamide monotherapy could be effective 
      and well tolerated in selected adults patients with partial onset seizures who 
      had achieved seizure freedom during lacosamide add-on therapy.
CI  - Copyright (c) 2015 British Epilepsy Association. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Lattanzi, Simona
AU  - Lattanzi S
AD  - Neurological Clinic, Department of Experimental and Clinical Medicine, Marche 
      Polytechnic University, Via Conca 71, 60020 Ancona, Italy. Electronic address: 
      alfierelattanzisimona@gmail.com.
FAU - Cagnetti, Claudia
AU  - Cagnetti C
AD  - Neurological Clinic, Department of Experimental and Clinical Medicine, Marche 
      Polytechnic University, Via Conca 71, 60020 Ancona, Italy.
FAU - Foschi, Nicoletta
AU  - Foschi N
AD  - Neurological Clinic, Department of Experimental and Clinical Medicine, Marche 
      Polytechnic University, Via Conca 71, 60020 Ancona, Italy.
FAU - Provinciali, Leandro
AU  - Provinciali L
AD  - Neurological Clinic, Department of Experimental and Clinical Medicine, Marche 
      Polytechnic University, Via Conca 71, 60020 Ancona, Italy.
FAU - Silvestrini, Mauro
AU  - Silvestrini M
AD  - Neurological Clinic, Department of Experimental and Clinical Medicine, Marche 
      Polytechnic University, Via Conca 71, 60020 Ancona, Italy.
LA  - eng
PT  - Journal Article
DEP - 20150314
PL  - England
TA  - Seizure
JT  - Seizure
JID - 9306979
RN  - 0 (Acetamides)
RN  - 0 (Anticonvulsants)
RN  - 563KS2PQY5 (Lacosamide)
SB  - IM
MH  - Acetamides/*therapeutic use
MH  - Adult
MH  - Anticonvulsants/*therapeutic use
MH  - Epilepsies, Partial/*drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lacosamide
MH  - Male
MH  - Middle Aged
MH  - Statistics, Nonparametric
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Antiepileptic drugs
OT  - Epilepsy
OT  - Lacosamide
OT  - Partial seizures
EDAT- 2015/04/22 06:00
MHDA- 2016/01/05 06:00
CRDT- 2015/04/21 06:00
PHST- 2014/12/29 00:00 [received]
PHST- 2015/02/02 00:00 [revised]
PHST- 2015/03/06 00:00 [accepted]
PHST- 2015/04/21 06:00 [entrez]
PHST- 2015/04/22 06:00 [pubmed]
PHST- 2016/01/05 06:00 [medline]
AID - S1059-1311(15)00073-4 [pii]
AID - 10.1016/j.seizure.2015.03.003 [doi]
PST - ppublish
SO  - Seizure. 2015 Apr;27:71-4. doi: 10.1016/j.seizure.2015.03.003. Epub 2015 Mar 14.